PR Newswire

PLEASANTON, Calif., Oct. 8, 2026

Eli Lilly and Company, Pfizer, Sanofi, UCB, and more share learnings speeding drug development, connecting trials, and modernizing quality and manufacturing

PLEASANTON, Calif. , Oct. 8, 2026 /PRNewswire/ -- At Veeva R&D and Quality Summit  on October 20-21 in Boston, Veeva Systems  (NYSE: VEEV) will bring together leading biopharmas, emerging biotechs, CROs, and sites — including Duke University, Eli Lilly and Company , Pfizer, Sanofi, Tolmar, UCB, and the University of Pennsylvania — to explain how they are driving new ways of working across drug development and quality.

Veeva will share its vision to power agentic biopharma for the industry with deep AI for clinical, regulatory, safety, and quality operations. New highlighted innovations include Veeva Falcon  agentic labor, Vault AI  agentic platform and agents, and new capabilities in Veeva Development Cloud  and Veeva Quality Cloud  applications.

More than 100 sessions will feature roadmaps, product highlights, and customer success, including:

Driving AI and automation for productivity and speed

• Eli Lilly and Company rolling out AI to improve productivity, accelerate submissions, and prepare the workforce of the future
• UCB  unifying safety for automated case processing, full signal to source traceability, and a data foundation for AI

Delivering connected trials for patients, sites, sponsors, and CROs

• DukeUniversity and another leading cancer center discussing scalable site-centric eSource strategies with direct data from EHR to EDC
• Sanofi building a connected, patient-first clinical ecosystem for a better trial experience

Modernizing quality and manufacturing to remove silos and create efficiencies

• Pfizer  piloting cloud LIMS to speed global delivery of medicines and set the path for AI
• Tolmar creating an integrated learning system for GxP compliance and professional development

More than 2,500 attendees come together to connect with industry peers at the Veeva R&D and Quality Summit. The event is open exclusively to life sciences professionals, who can register  and stay up to date on the agenda at veeva.com/Summit .

About Veeva Systems
Veeva delivers the industry cloud for life sciences with applications, agents, data, and consulting. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,500 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation , Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com .

Veeva Forward-Looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the fiscal year ended July 31, 2026, which you can find here (a summary of risks which may impact our business can be found on pages 33 and 34), and in our subsequent SEC filings, which you can access at sec.gov .

Contact:

Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com

SOURCE Veeva Systems